PRMT5-MTA Inhibitor Selectivity in MTAP-Deficient Tumor Cells
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current PRMT5 inhibitors exhibit strong inhibitory effects on both normal and tumor cells, leading to severe hematological toxicity and limiting their clinical application, while there is a lack of effective and selective PRMT5-MTA inhibitors.
Innovation Solution
Development of novel and highly selective PRMT5-MTA inhibitors, represented by compounds of formula (I) and (II), which target MTAP-deficient tumor cells by enhancing MTA and PRMT5 binding inhibition, reducing toxicity in normal cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-selective PRMT5 inhibitors (substrate-competitive or SAM-competitive inhibitors) are used, then strong inhibitory activity against PRMT5 and potent anti-tumor activity are achieved, but severe hematological toxicity occurs due to strong inhibition in both normal and tumor cells
Solution Approach 1:
The patent applies local quality by creating selective inhibition through MTAP deficiency-specific mechanism. The inhibitor only effectively inhibits PRMT5 in tumor cells that are MTAP-deficient, while having minimal effect on normal cells. This is achieved by exploiting the local difference in MTAP status between tumor and normal cells, making the inhibition specific to the tumor microenvironment rather than system-wide.
Solution Approach 2:
The patent uses MTA as an intermediary substance. MTA accumulates in MTAP-deficient tumor cells and serves as a selective binder to PRMT5. The inhibitor works through enhancing MTA binding to PRMT5, where MTA acts as a mediator that selectively targets PRMT5 in tumor cells without affecting normal cells, thus reducing toxicity while maintaining anti-tumor activity.
2Object-affected harmful factors
If MTA-cooperative PRMT5 inhibitors are developed to exploit MTAP loss, then selective inhibition in tumor cells is achieved, but the therapeutic window is limited by the need for MTAP deficiency
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of PRMT5 inhibitors to enhance their binding affinity and selectivity. By optimizing the molecular parameters of the inhibitor compounds, the patent achieves effective inhibition in MTAP-deficient tumor cells while minimizing off-target effects. This chemical optimization allows the inhibitor to work specifically in tumors with MTAP loss without requiring broader applicability across all tumor types.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds provide a safe therapeutic window for anti-tumor efficacy by selectively inhibiting PRMT5 activity in tumor cells, minimizing toxicity in normal cells.
Implementation Method 1
MTA specifically accumulates in MTAP-deficient tumor cells, enhancing MTA and PRMT5 binding inhibition can achieve selective inhibition of PRMT5 activity in tumor cells
Implementation Method 2
The loss of MTAP can lead to intracellular accumulation of MTA, which competes with SAM, the functional methyl donor substrate of PRMT5, for binding to PRMT5
Data Source
AI summary
The present invention provides a compound as a PRMT5-MTA inhibitor, which is a compound of formula (I) or a pharmaceutically acceptable salt, isotopic variant, tautomer, or stereoisomer thereof. The present invention also provides a pharmaceutical composition containing said compound and use thereof in the treatment of cancer.